The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022. The FDA's announcement comes months after drugmaker Novo Nordisk told the agency ...

Cambridge synthetic biology doyen Constructive Bio has been awarded a significant grant from Innovate UK to transform the ...

The update about the popular semaglutide injections from drug manufacturer Novo Nordisk follows just two months after the FDA said that shortages of tirzepatide injections Zepbound and Mounjaro ...

The semaglutide shortage has officially ended in the US—which means the GLP-1 drug industry is about to undergo massive changes. In the intervening years, a lucrative industry of telehealth ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

Is Compounded Semaglutide Effective for Weight Loss? This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Is compounded semaglutide effective for weight loss? Here’s the short ...

Semaglutide is a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor mimicking its activity. GLP-1 is an incretin hormone and enterogastrone that stimulates insulin ...

An update to the FDA drug shortage list on Feb. 21 listed the semaglutide shortage as being resolved. In a press release, Novo Nordisk said it is shipping all doses of the medication regularly to ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Semaglutide was tied to a small risk of nonarteritic anterior ischemic optic neuropathy (NAION) in adults with type 2 ...

A new study has found that semaglutide — the active substance in Ozempic and Wegovy — may help reduce alcohol cravings in people with AUD. Despite the availability of treatment options ...

Adults with type 1 diabetes had greater declines in HbA1c and body weight 1 year after being prescribed semaglutide or tirzepatide. Randomized controlled trials are needed to assess efficacy and ...